Intellia's in vivo CRISPR therapy first to succeed in Phase 3
Intellia Therapeutics体内CRISPR疗法率先在三期试验中取得成功

An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approval in the first half of next year.
一项在人体内直接使用CRISPR编辑基因的实验性疗法，刚在三期临床试验中取得成功——这是该技术的首次突破——有望在明年上半年获得美国食品药品监督管理局的批准。